
Yatharth Hospit. Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
N/A
Margin
N/A
Fundraise
N/A
Order
N/A
Capex
N/A
0 of 0 growth signals are positive — mixed outlook.
Full analysisRevenue guidance
- →FY27 revenue growth is expected to surpass last year's 37% YoY growth.
- →ARPOB (Average Revenue Per Occupied Bed) growth guidance for FY27 is around 9-10% YoY.
- →Newer hospitals have ARPOB around INR 40,000-50,000, expected to grow 8-10% annually.
- →EBITDA margin expected upwards of 24% for FY27, with new hospitals projected to reach 25-27% EBITDA margins within 2 years.
- →Capacity expansion targets 3,200 beds operational soon, with a goal to reach 5,000 beds within approximately 2.5 years, faster than the originally planned 3 years.
- →Growth focus remains on North India clusters (Delhi NCR, UP, Haryana, Rajasthan) with potential new metro clusters.
- →Expansion includes greenfield, brownfield, and acquisitions, aiming to add at least one new hospital per year.
- →Overall growth momentum expected to be sustained in coming years.
Margin guidance
- →Revenue growth for FY27 is expected to surpass last year's 37% Y-o-Y growth, with sustained momentum ahead.
- →EBITDA margin guidance for FY27 is around 24% to 25%, with expectations of maintaining or slightly improving this level in coming years.
- →Newer hospitals currently around breakeven are targeted to achieve EBITDA margins of 25-27% within two years.
- →ARPOB (Average Revenue Per Occupied Bed) is projected to grow at 8-10% annually over the next 2-3 years, with newer hospitals already clocking INR 40,000-50,000 ARPOB.
- →PAT margins have seen short-term pressure due to high capex and interest costs but expected to stabilize and improve as new assets mature and capex normalizes.
- →Management confident of achieving target bed capacity of 5,000 beds earlier than planned, supporting higher scale and earnings growth.
- →Debt levels are manageable with sufficient internal accruals to fund expansions, supporting sustainable profit growth.
3 more insights locked — sign up free to unlock
Fundraise plans
- →The company currently has a debt of around INR 300 crores, increased from INR 210 crores mainly due to INR 80 crores taken for acquisitions.
- →Going forward, they plan to utilize internal accruals to fund acquisitions and maintenance/growth capex in existing hospitals.
- →They do not intend to take fresh loans in the near term, so interest costs are expected to remain stable (Q1 interest cost INR 6.6 crores).
- →Management is comfortable with current debt levels, having capacity to take up to 2x trailing EBITDA at the group level.
- →No explicit mention of upcoming equity fundraising; focus is on using internal accruals and manageable debt.
- →The company is well-positioned with cash, debt capacity, and accruals to fund the remaining capex for adding 1,800 beds.
Order book
Capex plans
- →Capex per bed is expected to be around INR 75-80 lakhs, including greenfield, brownfield, and acquisitions.
- →The Gurugram facility construction is progressing and expected to go live by Q1 of the next fiscal year.
- →Brownfield expansions planned at Noida Extension and Greater Noida, with capacity additions expected in 15-18 months.
- →Total bed capacity to reach over 3,200 beds soon, aiming for 5,000 beds within the next 2.5-3 years, possibly earlier.
- →No significant fresh loans planned; capex funded through internal accruals and existing debt (currently around INR 300 crores).
- →Focus on acquisitions of premium assets with high ARPOB potential in cities where they operate.
- →Oncology equipment investments made recently for Faridabad and Model Town hospitals, contributing to capex.
- →ESOP schemes introduced to retain talent, supporting strategic human capital investment.
How does Yatharth Hospit. rank vs peers in Healthcare Services?
Pro featureSee full Healthcare Services sector rankings
How does Yatharth Hospit. rank in Healthcare Services?
Compare Yatharth Hospit. against every Healthcare Services company (Q1 FY27) on revenue, margins and earnings-call signals.